What is Supply Chain & Logistics and when do you need it?
Supply Chain and Logistics is the machinery that gets a finished, released drug from the manufacturing site to the wholesaler, the pharmacy, the hospital, or in some cases directly to the treatment center. It covers demand and supply planning, transportation, warehousing and storage at the right temperature, import and export and customs clearance, serialization and track-and-trace, distribution to 3PL and specialty channels, and the reverse flow of returns, recalls, and destruction. Manufacturing makes the product. Supply chain makes sure it actually reaches the patient, in spec, on time, every cycle, without a stockout and without a temperature excursion that forces you to scrap a lot.
You need this function as you move toward launch, not after. The hard parts have long lead times: qualifying a 3PL, validating shipping lanes and packaging, standing up serialization to meet DSCSA in the US or the EU Falsified Medicines Directive in Europe, and mapping the cold chain end to end. Sponsors typically start these conversations during late-phase clinical or right after a positive readout, because launch supply has to be sitting in the right distribution centers on day one of commercialization. Starting after approval is how launches slip.
How heavy this gets depends on the product. A room-temperature small-molecule tablet is a relatively standard distribution problem. A biologic that ships at 2 to 8 degrees C, or a frozen mRNA or cell therapy at minus 70 or in liquid nitrogen, turns logistics into a controlled, validated, monitored process where a single failed shipper can mean a destroyed batch. Autologous cell and gene therapies push this furthest: the supply chain has to maintain vein-to-vein chain-of-identity and chain-of-custody for a product made for one named patient, where a mislabeled or mishandled shipment is a patient-safety event, not just a logistics miss.
What does a Supply Chain & Logistics vendor actually do?
Most of this work is sourced from CDMOs that bundle distribution with manufacturing, specialist pharma 3PLs, cold-chain carriers, and serialization providers. A sponsor usually assembles a small set of these rather than buying one monolithic service, and the exact mix depends on temperature requirements, geography, and channel. The functions below are what you are actually contracting for.
- Demand and supply planning: sales forecasting, inventory positioning across distribution centers, safety-stock policy, and managing the swings between forecast and real pull-through so you neither stock out nor expire product on the shelf.
- Cold-chain and controlled-temperature distribution: qualified shippers and lanes for 2 to 8 C, frozen, and ultra-cold or cryogenic product, with temperature monitoring, excursion management, and stability-budget tracking against your approved shelf life.
- 3PL warehousing and order fulfillment: GDP-compliant storage, pick-pack-ship, lot and expiry control, and integration with your order-to-cash systems and the wholesaler and specialty-pharmacy channel.
- Serialization and track-and-trace: unit-level serialization, aggregation, and reporting to meet DSCSA in the US and EU FMD in Europe, plus the connections to your trading partners and the regulatory data hubs.
- Global trade, customs, and import-export: country registration logistics, customs clearance, duties and documentation, and managing the controlled-substance or import-license requirements that vary market to market.
- Returns, recalls, and reverse logistics: handling returns and destruction, recall execution and reconciliation, and the chargeback and reconciliation work that sits behind distribution in the US channel.
- Chain-of-identity and chain-of-custody for cell and gene therapy: vein-to-vein scheduling, courier management, and the labeling and custody controls that keep an autologous product matched to its patient end to end.
How do you choose a Supply Chain & Logistics CDMO or 3PL?
This is a higher-stakes choice than it looks, because supply chain failures show up as stockouts, scrapped lots, or a market that runs dry, all of which hit revenue directly. Price per pallet or per shipment is the least useful number to lead with. The checklist below is what separates a partner that protects your launch from one that becomes the reason it slips. Score two or three candidates against the same written scope, then audit the front-runner's site before you sign.
Temperature and modality fit is usually the deciding factor. A 3PL that runs room-temperature generics flawlessly may have no qualified cryogenic capability or cell-therapy custody process at all, and forcing your product onto the wrong infrastructure is how excursions and chain-of-custody breaks happen.
- Quality and GDP/GxP status: confirm Good Distribution Practice compliance, the relevant licenses for the markets you ship to, recent inspection history, and how the vendor handles deviations, temperature excursions, and CAPAs. Distribution sits under GDP, and for product moving straight from a manufacturing site, GMP responsibilities can extend into storage and handling.
- Capacity and lead time: real warehouse and lane capacity for your volume and temperature class, validated shipping lanes already in place for your geographies, and honest lead times to qualify a new lane or stand up a new distribution center. Cold-chain and cryogenic capacity is constrained and booked ahead.
- Modality and indication fit: proven handling for your exact product type, whether that is a stable small molecule, a 2 to 8 C biologic, a frozen mRNA or vaccine, or an autologous cell therapy needing chain-of-identity. Ask for comparable products they ship today, not a generic capability claim.
- Region and regulatory track record: coverage and licensing in the countries you will sell in, demonstrated DSCSA and EU FMD serialization compliance, customs and import-export experience for your markets, and a clean record with the regulators that inspect distribution.
- Data quality and visibility: real-time temperature and shipment monitoring, order and inventory data that integrates with your systems, accurate lot and expiry tracking, and audit trails under ALCOA+ data-integrity expectations rather than spreadsheets and after-the-fact reporting.
- IP and confidentiality: clear handling of your forecasts, customer data, and patient information (especially for cell and gene therapy), a quality agreement that spells out who owns release, recall, and reporting decisions, and confidentiality terms that hold up before you share a launch plan.